SCHEMBL3584470

SCHEMBL3584470

Cc1c(C(=O)N(C)Cc2ccccc2Cl)[nH]c(C(N)=O)c1S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TACR1 P25103 3/20 0.37
HSP90AA1 P07900 1/20 0.36
KCNJ6 P48051 2/20 0.32
KCNJ5 P48544 2/20 0.32
KCNJ3 P48549 2/20 0.32
ALDH1A1 P00352 3/20 0.32
HTT P42858 2/20 0.32
GAA P10253 1/20 0.32
BRD4 O60885 1/20 0.32
BRD3 Q15059 1/20 0.32
MAP2 P11137 2/20 0.32
ACLY P53396 1/20 0.32
TAS2R14 Q9NYV8 1/20 0.32
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.32
THRB P10828 1/20 0.32
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580259 0.94 MEN1 (0.39) MEN1KMT2ATACR1HSP90AA1KCNJ6
SCHEMBL3582557 0.93 MEN1 (0.41) MEN1KMT2ATACR1HSP90AA1KCNJ6
SCHEMBL3586121 0.92 MEN1 (0.44) MEN1KMT2ATACR1HSP90AA1KCNJ6
SCHEMBL3586897 0.91 KMT2A (0.42) MEN1KMT2ATACR1HSP90AA1KCNJ6
SCHEMBL3586766 0.91 KMT2A (0.38) MEN1KMT2AHSP90AA1ALDH1A1HTT
SCHEMBL3579793 0.90 CRHBP (0.40) MEN1KMT2AALDH1A1HTTGAA
SCHEMBL3587823 0.88 KMT2A (0.45) MEN1KMT2AHSP90AA1ALDH1A1HTT
SCHEMBL3579882 0.88 KMT2A (0.45) MEN1KMT2ATACR1HSP90AA1HTT
SCHEMBL3587000 0.87 MEN1 (0.40) MEN1KMT2ATACR1HSP90AA1KCNJ6
SCHEMBL3588435 0.86 KMT2A (0.36) MEN1KMT2AHSP90AA1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP claimed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E MEN1 4584/4885KMT2A 1816/4885TACR1 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.